A problem of proportions: estimates of metabolically-associated fatty liver and liver fibrosis in Australian adults in the 2012 national AusDiab study

  • 1.

    Younossi, ZM et al. Global epidemiology of nonalcoholic fatty liver disease – Meta-analytic assessment of prevalence, incidence and outcome. Hepatology 64(1), 73–84 (2016).

    Item

    Google Scholar

  • 2.

    Younossi, Z. et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 692672–2682 (2018).

    Item

    Google Scholar

  • 3.

    EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64(6):1388–1402 (2016).

  • 4.

    Dyson, J. et al. Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. J. Hepatol. 60(1), 110-117 (2014).

    Item

    Google Scholar

  • 5.

    Vernon, G., Baranova, A. & Younossi, ZM Systematic review: The epidemiology and natural history of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Food. Pharmacol. The. 34(3), 274-285 (2011).

    CASE
    Item

    Google Scholar

  • 6.

    Reig, M. et al. Should patients with NAFLD/NASH be questioned for HCC?. Transplantation 103(1), 39–44 (2019).

    Item

    Google Scholar

  • seven.

    Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67328–357 (2018).

    Item

    Google Scholar

  • 8.

    Rinella, ME Nonalcoholic fatty liver disease: a systematic review. JAMA 313(22), 2263-2273 (2015).

    CASE
    Item

    Google Scholar

  • 9.

    Das, K. et al. The non-obese population in a developing country has a high prevalence of nonalcoholic fatty liver disease and significant liver disease. Hepatology 51(5), 1593-1602 (2010).

    CASE
    Item

    Google Scholar

  • ten.

    Armstrong, MJ et al. Presence and severity of nonalcoholic fatty liver disease in a large prospective primary care cohort. J. Hepatol. 56(1), 234–240 (2012).

    Item

    Google Scholar

  • 11.

    Leung, M., Piao, C. & Sarkar, S. NAFLD Reference Models at a Major US Academic Center (Elsevier, 2020).

    Delivered

    Google Scholar

  • 12.

    Adams, LA, Knuiman, MW, Divitini, ML & Olynyk, JK Body mass index is a more powerful predictor of alanine aminotransaminase levels than alcohol consumption. J. Gastroenterol. Hepatol. 23(7pt1), 1089–1093 (2008).

    CASE
    Item

    Google Scholar

  • 13.

    Mahady, SE, Gale, J., Macaskill, P., Craig, JC, and George, J. Prevalence of elevated alanine transaminase in Australia and its relationship to metabolic risk factors: a cross-sectional study of 9 447 people. J. Gastroenterol. Hepatol. 32(1), 169-176 (2017).

    CASE
    Item

    Google Scholar

  • 14.

    Adams, LA, Waters, OR, Knuiman, MW, Elliott, RR & Olynyk, JK NAFLD as a risk factor for the development of diabetes and metabolic syndrome: an eleven-year follow-up study. A m. J. Gastroenterol. 104(4), 861–867 (2009).

    Item

    Google Scholar

  • 15.

    Fraser, A. et al. Alanine aminotransferase, gamma-glutamyltransferase and incident diabetes: British women’s heart and health study and meta-analysis. Diabetic treatments 32(4), 741–750 (2009).

    CASE
    Item

    Google Scholar

  • 16.

    Doi, Y. et al. Liver enzymes as a predictor of incident diabetes in a Japanese population: the Hisayama study. Obesity (Silver Spring) 15(7), 1841–1850 (2007).

    CASE
    Item

    Google Scholar

  • 17.

    Liu, Z., Que, S., Ning, H., Wang, L., and Peng, T. Elevated alanine aminotransferase is strongly associated with incident metabolic syndrome: a meta-analysis of prospective studies. PLOS ONE 8(12), e80596 (2013).

    ADS
    Item

    Google Scholar

  • 18.

    Roberts, Sask. et al. Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study. Med. J.Aust. 21577–82 (2021).

    Item

    Google Scholar

  • 19.

    Dunstan, DW et al. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)—Methods and response rates. Diabetes Res. Clin. Convenient. 57(2), 119-129 (2002).

    Item

    Google Scholar

  • 20.

    Tanamas, SK, Magliano, DJ, Lynch, B., Sethi, P., Willenberg, L, Polkinghorne, KR, et al. Aus Diab 2012: The Australian Diabetes, Obesity and Lifestyle Study. Baker IDI Heart and Diabetes Institute. https://www.baker.edu.au/-/media/documents/impact/ausdiab/reports/ausdiab-report-2012.pdf?la=en (2013).

  • 21.

    World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes (1999).

  • 22.

    Alberti, KGMM et al. Harmonization of metabolic syndrome. Traffic 120(16), 1640-1645 (2009).

    CASE
    Item

    Google Scholar

  • 23.

    WHO. World Health Organization. Obesity: preventing and managing the global epidemic: report of the WHO consultation on obesity. 1997.

  • 24.

    Hodge, A., Patterson, AJ, Brown, WJ, Ireland, P. & Giles, G. The Anti Cancer Council of Victoria FFQ: Relative validity of nutrient intakes versus weighted food records in young-to-old women mean in a study of iron supplementation. August. NZJ Public Health 24(6), 576–583 (2000).

    CASE
    Item

    Google Scholar

  • 25.

    Eslam, M. et al. A new definition of fatty liver disease associated with metabolic dysfunction: a consensus statement from international experts. J. Hepatol. 73(1), 202–209 (2020).

    Item

    Google Scholar

  • 26.

    Bedogni, G. et al. The Fatty Liver Index: A Simple and Accurate Predictor of Fatty Liver Disease in the General Population. BMC Gastroenterol. 6(1), 33 (2006).

    Item

    Google Scholar

  • 27.

    Carvalhana, S., Leitão, J., Alves, AC, Bourbon, M., and Cortez-Pinto, H. How good is the controlled attenuation parameter and fatty liver index for assessing fatty liver in the general population: correlation with ultrasound. Liver Int. 34(6), e111–e117 (2013).

    Item

    Google Scholar

  • 28.

    Meffert, PJ et al. Development, external validation and comparative evaluation of a new diagnostic score for fatty liver disease. A m. J. Gastroenterol. 109(9), 1404-1414 (2014).

    Item

    Google Scholar

  • 29.

    Koehler, EM et al. External validation of the fatty liver index for the identification of nonalcoholic fatty liver disease in a population-based study. Clin. Gastroenterol. Hepatol. 11(9), 1201-1204 (2013).

    Item

    Google Scholar

  • 30.

    Harrison, SA, Oliver, D., Arnold, HL, Gogia, S. & Neuschwander-Tetri, BA Development and validation of a simple NAFLD clinical scoring system to identify patients without advanced disease. Intestine 57(10), 1441 (2008).

    CASE
    Item

    Google Scholar

  • 31.

    Dong, MH, Bettencourt, R., Barrett-Connor, E. & Loomba, R. Alanine aminotransferase declines with age: the Rancho Bernardo study. PLOS ONE 5(12), e14254 (2010).

    ADS
    Item

    Google Scholar

  • 32.

    My, X. et al. Proportion of NAFLD patients with a normal ALT value in all NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol. 20(1), 10 (2020).

    Item

    Google Scholar

  • 33.

    Siddiqui, MS et al. Association between high normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology 145(6), 1271-1273 (2013).

    CASE
    Item

    Google Scholar

  • 34.

    Cuthbertson, DJ et al. External validation of fatty liver index and lipid accumulation product indices, using 1H magnetic resonance spectroscopy, to identify fatty liver disease in healthy controls and insulin-resistant obese individuals . EUR. J. Endocrinol. 171(5), 561–569 (2014).

    CASE
    Item

    Google Scholar

  • 35.

    Australian Institute of Health and Welfare. Overweight and obesity: an interactive overview (AIHW, 2019).

    Google Scholar

  • 36.

    Ruffillo, G. et al. Comparison of NAFLD fibrosis score and BARD score in the prediction of fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 54(1), 160-163 (2011).

    Item

    Google Scholar

  • 37.

    McPherson, S., Stewart, SF, Henderson, E., Burt, AD, and Day, CP Simple noninvasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with nonalcoholic fatty liver disease. Intestine 59(9), 1265-1269 (2010).

    Item

    Google Scholar

  • 38.

    Natarajan, Y. et al. Risk of cirrhosis and hepatocellular cancer in patients with non-alcoholic fatty liver disease and normal liver enzymes. Hepatology 721242-1252 (2020).

    CASE
    Item

    Google Scholar

  • 39.

    Howel, J. et al. Aiming for the elimination of viral hepatitis in Australia, New Zealand and the Pacific islands and territories: where we are now and the obstacles to achieving the World Health Organization’s targets by 2030 . J. Gastroenterol. Hepatol. 34(1), 40–48 (2018).

    Item

    Google Scholar

  • Comments are closed.